Unraveling the complexity of therapeutic drug monitoring for monoclonal antibody therapies to individualize dose in oncology
Abstract Monoclonal antibodies (Mabs) have become key drugs in cancer treatment, either as targeted therapies or more recently as immune checkpoint inhibitors (ICIs). The fact that only some patients benefit from these drugs poses the usual question in the field of onco‐hematology: that of the benef...
Main Authors: | Etienne Chatelut, Jeroen J. M. A. Hendrikx, Jennifer Martin, Joseph Ciccolini, Dirk Jan A. R. Moes |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-04-01
|
Series: | Pharmacology Research & Perspectives |
Online Access: | https://doi.org/10.1002/prp2.757 |
Similar Items
-
Monitoring monoclonal antibody delivery in oncology: the example of bevacizumab.
by: Guillaume Nugue, et al.
Published: (2013-01-01) -
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective
by: Félicien Le Louedec, et al.
Published: (2020-10-01) -
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
by: Mariona Cabo, et al.
Published: (2017-12-01) -
Monoclonal Antibodies as Neurological Therapeutics
by: Panagiotis Gklinos, et al.
Published: (2021-01-01) -
Therapeutic monoclonal antibody for Sporotrichosis
by: Sandro eAlmeida
Published: (2012-11-01)